Although specific ITGA2 inhibitors are not yet clinically available, future studies should investigate whether ITGA2 inhibition could synergize with TKIs to improve treatment outcomes and overcome resistance in CML patients. The gene discussed is ITGA2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.